Pediatric IBD Case Study
This article is a preprint and has not been peer-reviewed. Additional case reports or details may be added before final publication. The copyright holder is the author.
Case Report: Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy
Natasha R. Ryz, PhD*, Caroline MacCallum, MD (FRCPC Internal Medicine)**, Robert T. Brooke*
*Vitality Biopharma, Los Angeles, California, USA
**University of British Columbia, Vancouver, Canada
This case report describes a 13-year-old boy with Crohn’s disease who achieved clinical and biochemical remission after oral administration of cannabinoids. After years of disease, the patient had poor appetite and suffered from weight loss and stunted growth, and failed to achieve remission with conventional therapies including the TNF-α inhibitor infliximab. The patient received three oral doses daily of 3 mg of Δ9-tetrahydrocannabinol (THC) and 3 mg of cannabidiol (CBD). The patient and family reported almost immediate symptomatic improvement, with increased appetite and body weight, reduced inflammatory scores, and signs of clinical remission. C-reactive protein, erythrocyte sedimentation rate, and calprotectin scores were also obtained as objective measures of disease remission following cannabinoid therapy. In particular, the calprotectin improvement suggests disease-modifying activity and not merely symptomatic relief. This clinical data suggests that cannabinoids are useful for treatment of drug-resistant pediatric inflammatory bowel disease.